Navigation Links
Technologies in Medical Technology

Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine

EMERYVILLE, Calif., May 1 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), today announced it has received a quarterly royalty payment of approximately $1.5 million from Merz Pharmaceuticals GmbH (Merz) for sales of Memantine for the treatment of Alzheimer's...

B. Braun Medical Inc. to Demonstrate Infusion Systems Technologies at HIMSS 2009 Interoperability Showcase

Integrated Solution's Electronic Health Record Capability Highlighted BETHLEHEM, Pa., March 31 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun) said its Outlook(R) Safety Infusion System , DoseTrac(TM) Infusion Management Software and DoseLink(TM) Interfaces successfully completed ...

MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer

WOONSOCKET, R.I., March 19 /PRNewswire-FirstCall/ --MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) announced today that it has entered into a cooperative research and development agreement with Maxim Biotech, Inc. to develop products for the study of liver stem cells and liver cancer. ...

Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition

Varian to showcase products ranging from treatment planning software for radiation therapy to flat panel detectors for filmless X-ray imaging BEIJING, March 16 /PRNewswire-FirstCall/ -- Varian Medical Systems, Inc. (NYSE: VAR ) will showcase the full spectrum of the company's cancer treatme...

BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference

LYNBROOK, N.Y., March 10 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming Cowen ...

Neuro Kinetics: Research Suggests I-Portal(R) NOTC Data Shows Mild Traumatic Brain Injuries That Other Technologies Miss

Unique Case Study of Patient Before & After mTBI Accident Presentation at American Balance Society, Case Study on Web Site, New Help for Returning Vets PITTSBURGH, March 4 /PRNewswire/ -- With record numbers of American soldiers returning from Iraq and Afghanistan with brain injuries...

Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis

EMERYVILLE, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) today announced that an independent Data Safety Monitoring Board (DSMB) has determined that the current clinical trials of Viprinex(TM) for the treatment of acute ischemic stroke are...

InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer

BILTHOVEN and AMSTERDAM, The Netherlands, October 30 /PRNewswire/ -- InteRNA Technologies B.V. and VU university medical center in Amsterdam, VUmc, announce today the signing of a framework research agreement to develop microRNA (miRNA)-based diagnostics and therapeutics for cancer using InteR...

Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data

- Company Plans to Announce Interim Results in January 2009 and Final Trial Data in mid-2009 - EMERYVILLE, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) today announced that following a meeting with the U.S. Food ...

Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients

BOSTON, Sept. 24 /PRNewswire-FirstCall/ -- Cancer treatment specialists reported yesterday how new technologies are enabling them to provide faster, more accurate cancer treatments than was possible with earlier generations of radiotherapy technology. In presentations given at an "Emerging Tec...

Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America

CRANBURY, N.J., Sept. 23 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN ) announced it presented results from a Phase 1 clinical study with PL-3994, a novel, long-acting natriuretic peptide receptor A (NPRA) agonist under development for treatment of the chronic treatment of ...

BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronie's Disease

LYNBROOK, N.Y. Sept. 17 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (OTC Bulletin Board: BSTC), a biopharmaceutical company developing first in class collagenase based products, announced today the initiation of a U.S. Phase IIb clinical trial in Peyronie's disease for its inject...

Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials

EMERYVILLE, Calif., Aug. 12 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) today announced that enrollment into its two Phase 3 pivotal studies evaluating Viprinex(TM) (ancrod) for the treatment of acute ischemic stroke has reached the level of patients ...

New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times

First Patients Treated Using Next Generation CyberKnife System at Oklahoma CyberKnife Center SUNNYVALE, Calif., Aug. 5 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY ), a global leader in the field of radiosurgery, announced today that the first patients...

MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.

MONMOUTH JUNCTION, N.J., Aug. 5 /PRNewswire/ -- MicroDose Technologies Inc. (MicroDose) today announced that the first clinical milestone in its collaboration with Merck & Co., Inc., through a Merck affiliate, has been achieved, triggering the first payment under the global license agreement f...

Emisphere Technologies Announces the Launch of a Human Clinical Trial For Oral Parathyroid Hormone (PTH)

Phase I Study to Explore the Effects of Eligen(R) Delivery Technology on Healthy Postmenopausal Women CEDAR KNOLLS, N.J., June 30 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS ) announced today that Novartis Pharma AG has launched a Phase I study in...

Duke Licenses ALPHADAS(R), Logos Technologies EDC System to Accelerate its Early Phase Clinical Trials

LONDON, June 26 /PRNewswire/ -- Duke University Medical Center has licensed ALPHADAS(R) Logos Technologies electronic data capture (EDC) software to accelerate and streamline its early-phase clinical trials and to enable physicians to follow patients more closely. Researchers at Duke, which ...

Disc Motion Technologies Announces First Human Implants of True TSMS(TM) Device

ANKARA, Turkey, June 13 /PRNewswire/ -- Disc Motion Technologies announced the completion of the first surgical procedure to implant the True Total Spinal Motion Segment System (TM) (TSMS(TM)), the first total joint replacement system for the lumbar spine, featuring an artificial lumbar disc a...

Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents

Sahajanand Medical Technologies received positive results of nine month PAINT trials for Drug eluting stents, Infinnium and Supralimus. The results unveiled during plenary session of EuroPCR 2008-Barcelona. SURAT, India, May 20 /PRNewswire/ -- Sahajanand Medical Technologies Pvt. Ltd. (S...

Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994

CRANBURY, N.J., May 20 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN ) announced today that dosing has been initiated in a Phase 2a clinical study of PL-3994, a novel, long-acting natriuretic peptide receptor A agonist, in subjects with controlled hypertension. The study i...

CoreSpine Technologies Expands Spinal Disc Site Preparation Efforts

Emerging spinal company continues to focus on unmet needs of the lumbar disc MINNEAPOLIS, May 1 /PRNewswire/ -- CoreSpine Technologies, LLC, an emerging spinal device company announced today the expansion of its platform technology for spinal implant procedures...

Emisphere Technologies Announces Positive Results From Animal Studies on Oral B12 Using eligen(R) Technology

CEDAR KNOLLS, N.J., Feb. 7 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS ) announced today that recent animal studies have demonstrated proof of concept that absorption of oral vitamin B12 using the company's proprietary eligen(R) technology was 15-30 times greater than...

TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY

New AcuCare Programs Automate the Interface between Health Assessments for Patients and the Generation of Customized Care Treatment Plans AUBURN, Calif., Jan. 22 /PRNewswire/ -- TCS Healthcare Technologies, an industry leader in the development of medical management software applications th...

Senesco Technologies Initiates Preclinical Studies for Cancer Target

NEW BRUNSWICK, N.J., Dec. 5 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT ) announced today, that it has initiated preclinical lab studies at Mayo Clinic focused on multiple myeloma. These studies will further test the ability of Senesco's Factor...

King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction

CRANBURY, N.J. and BRISTOL, Tenn., Aug. 30 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN ) and King Pharmaceuticals, Inc. (NYSE: KG ) announced today that they have delayed plans for the initiation of Phase 3 clinical trials with bremelanotide, a first in class melanocortin...

Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies

Olympus Corporation to Support the Joint Program through the Provision of Novel Imaging Systems Collaboration Will Bring Innovative Fluorescent Imaging Agent and System Technologies into Clinical Trials in Ovarian Cancer PHILADELPHIA, TOKYO and WOBURN, Mass, J...

AVAX Technologies Presents Results of Phase I-II M-Vax Trial at Annual Meeting of American Association for Cancer Research

PHILADELPHIA--(BUSINESS WIRE)--Apr 16, 2007 - AVAX Technologies, Inc. (OTCMarket:AVXT.OB) today announces that it is presenting the initial results of its Phase I-II trial of M-Vax(TM) for patients with metastatic melanoma at a Clinical Research session of the meeting of the American Association fo...

OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting

VANCOUVER, April 17, 2007 /PRNewswire/ - OncoGenex Technologies Inc. announced today data from a Phase II clinical trial of OGX-011 in combination with docetaxel in patients with metastatic breast cancer (MBC). Data was presented by the National Cancer Institute of Canada - Clinical Trials Group a...

Micell Technologies Presents Data on Novel Drug-Eluting Stents

RALEIGH, N.C., April 18, 2007 /PRNewswire/ -- Micell Technologies announced today that the Company will be presenting data on use of its supercritical fluid (SCF) surface modification technology for drug-eluting stents at the upcoming Society for Biomaterials 2007 Annual Meeting, April 19-21 2007 ...

Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at 20th International Conference on Antiviral Research Meeting

REDWOOD CITY, Calif., May 02, 2007 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. announced today that a presentation was made today at the 20th International Conference on Antiviral Research being held in Palm Springs, California, on a non-nucleoside hepatitis C virus (HCV) polymerase inhi...

Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction

CRANBURY, N.J. and BRISTOL, Tenn., May 09, 2007 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. and King Pharmaceuticals, Inc. today announced plans to present the results from two bremelanotide Phase 2b studies of men with erectile dysfunction (ED). The presenters are Jed Kaminetsky, MD, Cli...

Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide

CRANBURY, N.J., and BRISTOL, Tenn., May 22, 2007 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. and King Pharmaceuticals, Inc. reported today that data from Study 16 and Study 17 of the Phase 2B clinical trial program evaluating bremelanotide in men with erectile dysfunction (ED) were presen...

Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

HORSHAM, Pa.--(BUSINESS WIRE)--Jul 9, 2007 - Neose Technologies, Inc. (NasdaqGM:NTEC) announced today that it will present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference held at the Mandarin Oriental Hotel in New York City from July 10-12, 2007. The Company's presentation is...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...ase. Isis benefits from its partners as they advance RNA-based technologies and develop drugs that incorporate Isis' technology resulting in financial ...d subsidiary, and the therapeutic and commercial potential of the Company's technologies and products in development. Any statement describing Isis' goals, expecta...

Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership

...on, its mission is to develop and apply innovative technologies to the discovery of new biologic processes and new...n develops and applies integrated state-of-the-art technologies in chemistry, biology, automation, and information...nd metabolic as well as infectious disease. These technologies cut across the life sciences, and include genomics...

DNA Helps Reunite Children With Their Families

... industry through a $500,000 grant from The Life technologies Foundation to develop the DNA-PROKIDS Project ...er has been responsible for the development of DNA technologies and systems for parentage testing, forensic testin...o http://www.hsc.unt.edu/ About Life technologies Life...

Study Shows Brain Fitness can Save Medicare Billions

...omputer-based programs. More than 30 articles in leading science and medical journals show that in randomized controlled trials the company's patented technologies significantly increase processing speed, improve memory and attention and enhance quality of life. Posit Science has received grants from the National...

CTMM Becomes One of the World's Largest Public-Private Partnerships in Translational Medical Research

...About CTMM CTMM (Center for Translational Molecular Medicine) is a Netherlands-based public-private partnership dedicated to the development of technologies in molecular medicine that enable early diagnosis and personalised treatment for oncology, cardiovascular, neurodegenerative and infectious/auto-immun...

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

....janssen.com/ . About NanoCrystal ((R)) Technology and Elan Drug technologies INVEGA(R) SUSTENNA(TM) utilizes the NanoCrystal((R)) Technology, which is a proprietary technology developed by Elan Drug technologies through Elan Pharma International Limited and other Elan affiliates. NanoCr...

Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program

...g of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vi...
Other Tags
(Date:8/21/2014)... 2014 /PRNewswire-iReach/ -- LiveScan Service Provider  Binary ... a partnership with Gabriel Health Institute, one of ... Certified Nursing Assistant preparatory schools. The agreement ... member of Binary,s LiveScan service provider,s owner/operator team; ... its service capabilities by widening the service ...
(Date:8/21/2014)... a finding that has implications for life in other ... the solar system, LSU Associate Professor of Biological Sciences ... Science Foundation, or NSF, this week published a paper ... that lies 800 meters (2600 feet) beneath the surface ... ecosystems.", Given that more than 400 subglacial lakes and ...
(Date:8/21/2014)... 18-22, 2014 , WHERE: , San Diego ... CA 92101 , WHAT: , Invited and ... latest research in human genetics. Examples of sessions ... on rare genetic variants in health and disease, ... sun sensitivity (Saturday, Oct. 18, 5:30-7:30 pm) , ...
Breaking Biology News(10 mins):LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4American Society of Human Genetics 2014 Annual Meeting 2
(Date:8/23/2014)... August 23, 2014 On Monday, August ... a data breach suffered by Community Health Systems, ... compromise of 4.5 million records containing Personally Identifiable Information ... According to Mandiant, who was engaged to investigate the ... an advanced group of cyber attackers based in China, ...
(Date:8/23/2014)... 2014 Pixel Film Studios, a leader of ... release of ProIntro Vol.3, a customizable title tool for ... tile just by dragging ProIntro Vol.3 in their timeline" says ... a definite time saver and i think our users will ... beautifully designed titles made with Final Cut Pro X users ...
(Date:8/23/2014)... (PRWEB) August 23, 2014 Teen drug ... Carolina. It’s no different in Wilmington, NC. Substance abuse ... are falling victim to drug and alcohol dependency in ... are looking to overcome substance abuse, but don’t know ... adolescent treatment facility can be a challenge because most ...
(Date:8/22/2014)... The IT manager of Top10BestSEOHosting.com is ... several years. He has recently announced that GoDaddy ( ... in 2014. , GoDaddy is a popular supplier of ... great hosting solutions at affordable rates. It offers three ... hosting plans depend on the length of the contract. ...
(Date:8/22/2014)... Today, Zane Benefits, the #1 Online ... Health Plans. , According to Zane Benefits, employers are ... lower the cost of healthcare without reducing coverage for ... however, can be confusing. , The new guide contains ... main types of ABHPs. It also explains the ...
Breaking Medicine News(10 mins):Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 3Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 4Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:Troubled Teens Wilmington Helpline Guides Adolescents to the Path of Recovery 2
Other Contents